Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
June 24, 2019 07:30 ET
|
Minerva Neurosciences, Inc
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexantKey secondary endpoint,...
Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
May 13, 2019 08:15 ET
|
Minerva Neurosciences, Inc
Potential first-in-class, oral specific orexin-2 inhibitor demonstrates statistically significant improvement in MADRS scores at 6 weeks compared to placebo Well tolerated, with adverse events similar...
Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates
March 12, 2018 07:30 ET
|
Minerva Neurosciences, Inc
Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder Planning for commercialization moves forward Management to host conference call today at...
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
September 05, 2017 08:00 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates
August 03, 2017 07:30 ET
|
Minerva Neurosciences, Inc.
FDA feedback on clinical trial design and completion of bridging study with new formulation enable initiation of Phase 3 trial with MIN-101 to treat negative symptoms of schizophrenia in second half...
Minerva Announces Amended Agreement for MIN-202 in Insomnia
May 31, 2017 16:05 ET
|
Minerva Neurosciences, Inc.
Minerva to gain global strategic control over development of MIN-202 for insomnia Janssen cash payments to Minerva of up to $70 million, including $30 million upfront All shares in Minerva held by...
Agile Therapeutics Appoints Seth H. Z. Fischer to its Board of Directors
July 28, 2016 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 28, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) today announced the appointment of Seth H. Z. Fischer to the Company's Board of Directors, effective July...
Minerva Neurosciences Reports First Quarter 2016 Financial Results and Business Updates
May 03, 2016 07:30 ET
|
Minerva Neurosciences, Inc
Positive top line results of trials with MIN-202 highlight first quarter Last patient visits completed in trials with MIN-101 and MIN-117; data expected in second quarter WALTHAM, Mass., May 03,...
Agile Therapeutics Appoints Ajit S. Shetty, Ph.D., to Its Board of Directors
February 24, 2016 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) today announced that Ajit S. Shetty, Ph.D., has been appointed to the Company's Board of Directors,...
DiamiR Announces Research Collaboration With Johnson & Johnson Innovation
January 11, 2016 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - January 11, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests, announced today that it has entered into a research...